This article was originally published on 17 December 2013 as part of the VacZine Analytics ExpertREACT series. It is reproduced here for archival purposes. Market conditions, pipeline statuses and regulatory positions described reflect the state of knowledge at that date.
The Cdiffense Phase III trial
In August 2013, Sanofi Pasteur announced the start of its Phase III trial "Cdiffense" (NCT01887912) evaluating the efficacy of a C.diff toxoid vaccine for primary CDI prevention. The vaccine - a purified preparation of C.diff toxoids A and B given as three IM injections (0, 7 and 30 days) - is enrolling approximately 15,000 adults aged over 50 years at 200 sites across 17 countries. Primary completion is expected December 2017, suggesting potential approval in early 2019.
Estimated annual economic burden of Clostridium difficile infection in the US alone, driven by prolonged hospitalisation
Why the US is the primary market
VacZine Analytics estimates that approximately 75% of CDI cases in major markets in 2013 occurred in the United States. US CDI incidence rates are now comparable to those seen in the UK during 2004-2007, which triggered government-mandated infection control. However, achieving similar outcomes in the fragmented US healthcare system is more challenging. CDI is also under consideration for inclusion in the Centers for Medicare & Medicaid Services (CMS) Hospital Value-Based Purchasing (VBP) Programme by 2017, which would impose financial penalties on high-CDI hospitals - potentially accelerating vaccine adoption.
Broader pipeline
Pfizer and Valneva (formerly Intercell) also had C.diff vaccines in earlier clinical development. With Staphylococcal and Pseudomonal vaccine programmes suffering setbacks, C.diff is increasingly likely to emerge as the first licensed nosocomial vaccine - a landmark for hospital infection prevention.
"A multipronged vaccination strategy targeting multiple risk groups, with emphasis on the US, is the way forward for the C. difficile vaccine market."
European dynamics
In Europe, CDI incidence rates are rising and the EU Parliament adopted a resolution in October 2013 calling for C.diff to move up the political agenda. However, incidence rates appear lower than in the US and the fragmented European reimbursement environment makes demonstrating cost-effectiveness - particularly for a vaccine without a "herd effect" - more challenging.